Drugs / HRS9432
last change Jun 2026 re-read 2 minutes ago

HRS9432

Developed for
candidiasis
Investigated by
Fujian Shengdi Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06194201 Apr 2024 → Jun 2026 candidiasis Fujian Shengdi Pharmaceutical Co., Ltd. Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HRS9432 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194201
Route Intravenous “Dosing frequency: intravenously once week” NCT06194201